United-Guardian

UG

Market cap $32.2M

UG reports higher y/y earnings and sales in Q1, driven by strong demand for Renacidin and increased purchases of cosmetic ingredients.

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

HAUPPAUGE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2026. First quarter sales increased from $2,481,127 in 2025 to $2,872,222 in 2026, with net income increasing from $560,895 ($0.12 per share) to $818,902 ($0.18 per share).

UG reports a sharp drop in 2025 earnings as weak cosmetic sales weigh on results, despite growth in pharmaceuticals and medical lubricants.

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025.

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.

HAUPPAUGE, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2025. Sales for the nine-month period ended September 30th decreased from $9,705,262 in 2024 to $7,583,613 in 2025 and net income decreased from $2,747,151 ($0.60 per share) to $1,456,162 ($0.32 per share). Third quarter sales decreased from $3,060,113 in 2024 to $2,264,261 in 2025 and net income decreased from $865,484 ($0.19 per share) to $268,441 ($0.06 per share).

United-Guardian's Q2 earnings fall on weak cosmetic sales, partly offset by gains in pharmaceuticals and medical lubricants, with recovery hopes ahead.

United-Guardian (UG), a specialty ingredients manufacturer known for its pharmaceutical, cosmetic, and medical lubricant products, released its second quarter fiscal 2025 results on August 8, 2025. Alongside net income (GAAP) falling to $626,826, as cosmetic ingredient sales dropped sharply in the first six months of 2025 due to distributor inventory issues.